BIOCON
Biocon Limited (biocon) Announces U.S. Launch of Yesafili™ Biosimilar
Biocon Limited (BIOCON) announces the U.S. launch of Yesafili™, a biosimilar to Regeneron’s Eylea® 2 mg, expanding access to eye treatment.
Biocon Limited (NSE: BIOCON), an innovation-led global biopharmaceutical company, announced the commercial launch of Yesafili™ (aflibercept) in the United States. Yesafili™, a biosimilar of Regeneron’s Eylea® 2 mg, is a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions. The product was previously approved and granted interchangeable designation by the U.S. Food and Drug Administration in May 2024, allowing substitution at the pharmacy level in accordance with state laws.
Significant Milestone
Shreehas Tambe, CEO & Managing Director, Biocon Ltd., said, “The launch of Yesafili™ in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions. This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea® 2 mg, advancing access to life-changing medicines for patients around the world.”
Market Potential
An estimated 19.8 million Americans are living with age-related macular degeneration (AMD), while U.S. sales of aflibercept reached approximately $5.89 billion in 2023, underscoring the growing need for effective treatment options. The approval for Yesafili™ was based on a comprehensive package of analytical, nonclinical, and clinical data, which confirmed that Yesafili™ is highly similar to Eylea® 2 mg.
To report SUSPECTED ADVERSE REACTIONS, contact Biocon at 1-833-986-1468.
For more information, visit www.biocon.com.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Biocon Limited
Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Biocon gains 18.4% over three months and trades near its 52-week highs. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock trades at 82% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 18.4% in three months on 15.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Biocon Limited.
BIOCON
Biocon Limited (biocon) Secures 10-year Supply Contract for Pertuzumab in Brazil
Biocon Limited (BIOCON) secures a 10-year supply contract for Pertuzumab in Brazil, marking a significant milestone in advancing HER2-positive breast cancer.
Biocon Limited (NSE: BIOCON) has announced the signing of a 10-year supply contract for Pertuzumab in Brazil, marking a significant milestone in advancing HER2-positive breast cancer therapy. The contract was signed with Bahiafarma and Bionovis, under Brazil’s Productive Development Partnership (PDP) program. The consortium received 100% allocation under Brazil’s 10-year PDP program for Pertuzumab, providing exclusive access to Brazil’s public healthcare market.
Strategic Partnership
Shreehas Tambe, CEO & Managing Director of Biocon, emphasized the transformative potential of strong partnerships in building local capabilities and expanding access to affordable medicines. This contract enables Biocon to reach more patients with HER2-positive breast cancer and address an important healthcare need at scale.
Market Impact
The PDP framework supports the long-term adoption of Biocon’s product within Brazil’s public oncology network. The product will undergo phased localization in Brazil in the mid to long term, ensuring sustainable access to this important cancer therapy. This partnership also contributes to Brazil strengthening its capacity to produce essential medicines for its Unified Health System (SUS).
Future Prospects
As part of the PDP, Biocon will receive milestone payments and a share of revenues generated from the Brazil PDP opportunity over a 10-year period. This agreement not only supports better patient outcomes but also helps build a stronger, more resilient healthcare ecosystem in Brazil.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Biocon Limited
Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Biocon moves sideways over three months, with neither buyers nor sellers taking control. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 18 of recent sessions versus 12 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.
BIOCON
Biocon Limited (biocon) Q1 FY27: Revenue Up 9%, Biosimilars Lead Growth
Biocon Limited (BIOCON) reports Q1 FY27 results with a 9% revenue increase, driven by strong biosimilars performance.
Biocon Limited (BIOCON) has reported its Q1 FY27 earnings, showcasing a 9% increase in total revenue to ₹4,391 crore. The company’s biosimilars segment has been the primary driver of this growth, with revenues up 16% year-on-year to ₹2,855 crore. The generics segment also contributed positively with a 21% YoY revenue increase to ₹760 crore. However, the services segment faced challenges, with revenues declining 16% to ₹736 crore.
Biosimilars Segment Performance
The biosimilars division has shown robust performance, with EBITDA up 10% YoY to ₹728 crore. The R&D spend increased to 7% of revenue, reflecting the company’s focus on sustaining its growth momentum. The segment’s EBITDA margin stood at 25%, driven by successful market launches and operational efficiencies.
Generics Segment Insights
The generics segment continued to perform well, driven by the generic liraglutide, which saw strong uptake across multiple markets, including the USA. The EBITDA margin improved significantly, up by over 250 basis points QoQ to 7%.
Services Segment Challenges
The services segment faced headwinds due to lower offtake from a key biologics client and forex hedge losses. Despite cost optimization initiatives, revenues declined 16% to ₹736 crore. The company remains optimistic about the second half of FY27, with a focus on cost-competitiveness and strategic collaborations.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Biocon Limited
Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Biocon rises 11.2% over three months, with buying pressure holding steady. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock trades at 81% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. The stock rises 11.2% in three months on 15.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Biocon Limited.
BIOCON
Biocon Limited Q1 FY27: Total Income at Rs 4,391 Cr, Up 9%
Biocon Limited (BIOCON) reports a 9% rise in total income to Rs 4,391 Cr for Q1 FY27, driven by strong Biopharma growth.
Biocon Limited (NSE: BIOCON) announced its consolidated financial results for the first quarter of FY27, showing a total income of Rs 4,391 crore, up 9% year-on-year. The focus keyword, Biocon Limited BIOCON Q1 FY27 Total Income, highlights the company’s financial performance. The revenue growth was driven by a robust performance in the Biopharma segment.
Biopharma Revenue Growth
The Biopharma business saw a 17% year-on-year increase in revenue, bolstered by recent biosimilar and generic product launches across key markets. Biosimilars revenue rose 16% to Rs 2,855 crore, while generics revenue increased 21% to Rs 760 crore.
EBITDA and Net Profit
Consolidated EBITDA stood at Rs 902 crore, with a margin of 21%. The net profit before exceptionals was Rs 145 crore, reflecting improved profitability in the Biopharma business. The company’s leadership remains confident about the long-term opportunities across North America, its biggest market.
Forward-Looking Statement
Kiran Mazumdar-Shaw, Executive Chairperson, emphasized the company’s focus on translating strategic investments into sustainable growth and long-term value creation. The company expects growth momentum to accelerate through the year, driving a stronger second-half performance.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Biocon Limited
Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.
Biocon posts a 10.9% three-month gain, but softens in the last few weeks. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gives back 1.1% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The stock rises 10.9% in three months on 15.3% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Biocon Limited.
-
CUMMINSIND3 days agoCummins India Limited (cumminsind) Unveils Next-generation Power Solutions at Bauma Conexpo India 2026
-
Industrials3 days agoWestern Carriers (india) Limited Launches Bulk Tiles Train at Morbi Terminal
-
CARTRADE3 days agoCartrade Tech Limited (cartrade) Expands OLX India’s Elite Buyer for Businesses
-
Auto Parts3 days agoUno Minda Limited Announces Four Major Strategic Expansions with ₹1,415 Crore Investment
-
AUROPHARMA3 days agoAurobindo Pharma Limited Receives Final Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
-
EMBDL3 days agoEmbassy Developments Limited (embdl) Launches Embassy Origins in North Bengaluru
-
IZMO3 days agoIzmo Limited (NSE: IZMO) Unveils Silicon Photonics Modules at Semicon India 2026
-
Basic Materials3 days agoS H Kelkar and Company Limited (SHK) Mourns the Loss of Chairman Mr. Ramesh Vinayak Vaze